Teva Pharmaceutical has decided to suspend the ENFORCE Phase III clinical development programme of fremanezumab in cluster headache.
A futility analysis of a Phase III clinical trial for episodic cluster headache showed that the therapeutic is not likely to meet the primary endpoint of a mean change in the weekly average number of cluster headache attacks from baseline during the four-week treatment duration.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Based on the analysis of the results, Teva decided to suspend the clinical trial programme, which also includes a long-term safety study.
The programme also comprised a chronic cluster headache trial that was discontinued in June last year after a futility analysis found that the primary endpoint would not be met.
However, Teva intends to continue developing fremanezumab in other indications. The compound is currently being assessed in a Phase II trial to treat post-traumatic headaches.
Teva Pharmaceutical Global Specialty Clinical Development head Tushar Shah said: “Despite these results, we are continuing to evaluate if fremanezumab treatment can provide clinical benefits in additional diseases where anti-calcitonin gene-related peptide (CGRP) therapy may play a role in its pathophysiology.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataFremanezumab is a humanised monoclonal antibody designed to bind to and prevent the calcitonin gene-related peptide (CGRP) ligand interaction with its receptor.
In September last year, the US Food and Drug Administration (FDA) approved the use of fremanezumab, under the brand name Ajovy, as a preventive treatment for migraine in adults.
The approval is based on data from two Phase III trials that assessed the drug as a stand-alone preventive therapy, as well as in combination with oral preventive treatments.
According to the results, patients had a decrease in monthly migraine days during a 12-week period.
